No Data
JUNSHI BIO (688180.SH): Treloparib has been approved for marketing by the Singapore Health Sciences Authority.
On March 26, Gelonghui reported that JUNSHI BIO (688180.SH) announced that the company received notification that the marketing authorization application for Toripalimab (Singapore commodity name: LOQTORZI) in combination with Cisplatin and Gemcitabine for the first-line treatment of adult patients with recurrent, unresectable or radiotherapy-resistant, or metastatic nasopharyngeal carcinoma has been approved by the Health Sciences Authority (HSA) of Singapore. Toripalimab has become the first and only approved tumor immunotherapy drug for nasopharyngeal carcinoma in Singapore.
JUNSHI BIO (01877) returns the idle raised funds temporarily used to supplement working capital.
JUNSHI BIO (01877) announced that the third Board of Directors meeting will be held on March 28, 2024...
Junshi Biosciences Gets Nod to Market Hepatocellular Carcinoma Drug
Express News | Junshi Biosciences Announces Approval of Snda for Toripalimab in Combination With Bevacizumab for 1St-Line Treatment of Advanced Hepatocellular Carcinoma
Junshi Biosciences Announces Approval of SNDA for Toripalimab in Combination With Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
Express News | Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab in Combination With Bevacizumab by Nmpa
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
